Aminosalicylic acid microbiology: Difference between revisions

Jump to navigation Jump to search
No edit summary
Line 5: Line 5:
==Microbiology==
==Microbiology==


The aminosalicylic acid MIC for M. tuberculosis in 7H11 agar was less than 1.0 μg/mL for nine strains including three multidrug resistant strains, but 4 and 8 μg/mL for two other multidrug resistant strains. The 90% inhibition in 7H12 broth (Bactec) showed little dose response but was interpreted as being less than or equal to 0.12-0.25 μg/mL for eight strains of which three were multi-resistant, 0.50 μg/mL for one resistant strain, questionable for four non-resistant strains and greater than 1μg/mL for one non-resistant and three resistant strains. Aminosalicylic acid is not active in vitro against M. avium.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = PASER (AMINOSALICYLIC ACID) GRANULE, DELAYED RELEASE [JACOBUS PHARMACEUTICAL COMPANY, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6 | publisher =  | date =  | accessdate =  }}</ref>  
The aminosalicylic acid MIC for M. tuberculosis in 7H11 agar was less than 1.0 μg/mL for nine strains including three multidrug resistant strains, but 4 and 8 μg/mL for two other multidrug resistant strains. The 90% inhibition in 7H12 broth (Bactec) showed little dose response but was interpreted as being less than or equal to 0.12-0.25 μg/mL for eight strains of which three were multi-resistant, 0.50 μg/mL for one resistant strain, questionable for four non-resistant strains and greater than 1μg/mL for one non-resistant and three resistant strains. Aminosalicylic acid is not active in vitro against M. avium.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = PASER (AMINOSALICYLIC ACID) GRANULE, DELAYED RELEASE [JACOBUS PHARMACEUTICAL COMPANY, INC.] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6f2753dc-5f0c-4f49-9335-e519afb69ba6 | publisher =  | date =  | accessdate =  }}</ref>
 


==References==
==References==

Revision as of 15:55, 24 December 2013

Aminosalicylic Acid
PASER® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: ; Chetan Lokhande, M.B.B.S [2]

Microbiology

The aminosalicylic acid MIC for M. tuberculosis in 7H11 agar was less than 1.0 μg/mL for nine strains including three multidrug resistant strains, but 4 and 8 μg/mL for two other multidrug resistant strains. The 90% inhibition in 7H12 broth (Bactec) showed little dose response but was interpreted as being less than or equal to 0.12-0.25 μg/mL for eight strains of which three were multi-resistant, 0.50 μg/mL for one resistant strain, questionable for four non-resistant strains and greater than 1μg/mL for one non-resistant and three resistant strains. Aminosalicylic acid is not active in vitro against M. avium.[1]

References

  1. "PASER (AMINOSALICYLIC ACID) GRANULE, DELAYED RELEASE [JACOBUS PHARMACEUTICAL COMPANY, INC.]".

Adapted from the FDA Package Insert.